Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC
Clinical trial NCT03425331 · TERMINATED
Trial details
- NCT number
- NCT03425331
- Sponsor
- Dana-Farber Cancer Institute
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-04-10
- Primary completion
- 2020-05-18
- Enrollment
- 5
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.